[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380282":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":57,"collaborators":18,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":18,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Third Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TAF group","ACTIVE_COMPARATOR","100 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long unless the patient achieves HBsAg loss.",[13],"Drug: Tenofovir alafenamide Fumarate",{"label":15,"type":16,"description":17,"interventionNames":18},"Observation group","NO_INTERVENTION","100 patients would not receive treatment from baseline to life-long.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tenofovir alafenamide Fumarate","Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.",[9],[26],"Vemlidy",[28],{"name":29,"affiliation":5,"role":30},"Liang Peng, Doctor","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":18,"email":36},"Qiumin Luo, Doctor","CONTACT","+8613632399075","lqiumin@126.com",{"name":29,"role":34,"phone":38,"phoneExt":18,"email":39},"+8613533978874","pzp33@hotmail.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Third Affiliated Hospital of Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510630","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56],{"name":29,"role":34,"phone":38,"phoneExt":18,"email":39},{"type":30,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Liang Peng","Professer","100380282","nucleoside-acid-analogues-treatment-in-patients-with-normal-alt-and-positive-hbvdna-100380282",false,"NCT04231565","Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.","Study on Therapeutic Effects and Safety of Nucleoside (Acid) Analogues Treatment in Patients With Chronic Hepatitis B With Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA: a Randomized Controlled Trial","ALTHBV","Inclusion Criteria:\n\n* Positive hepatitis b surface antigen and hepatitis b antibody \\> 0.5 year;\n* Age from 18 to 65 years old;\n* Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;\n* Positive Hepatitis b virus(HBV);\n* Do not receive nucleotide\u002Fnucleoside analogues or interferon treatment in the past half year.\n\nExclusion Criteria:\n\n* Other active liver diseases;\n* Hepatocellular carcinoma or other malignancy;\n* Pregnancy or lactation;\n* Human immunodeficiency virus infection or congenital immune deficiency diseases; 5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering inappropriate.","ALL","18 Years","65 Years",{"count":72,"type":73},200,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus DNA.",[79],"Hepatitis B Virus",[81,82,83],"hepatitis B virus","nucleoside","nucleotide","2024-02-28",{"date":86,"type":87},"2024-03-01","ACTUAL",{"date":89,"type":87},"2020-06-04",{"date":91,"type":73},"2027-07-01",{"name":5,"class":6},1]